Pfizer
Animal Health to Expand Access to E. coli
O157 Vaccine from Epitopix for Beef
Cattle
Salmonella
Newp
or
t
Cattle Vaccine Also Part of Pfizer Animal Health’s Licensing Agreement
NEW
YORK, June 11, 2010 — Pfizer
Animal Health today furthered its commitment to safe food from cattle by
announcing a global licensing agreement with Epitopix that will expand access to
its conditionally licensed Escherichia
Coli Bacterial Extract vaccine* to U.S. cattle producers this
fall.
“Pfizer
Animal Health supp
or
ts cattle producers’ continuing strides against harmful bacteria, often the
most frequent causes of food borne illnesses in people,”
said Juan Ramón Alaix,
president, Pfizer Animal Health. “We want m
or
e cattle producers to benefit from this imp
or
tant vaccine to help reduce the prevalence and shedding of E.
coli.”
The
U.S. Department of Agriculture (USDA) granted a conditional license last
year to Epitopix f
or
this first and only Escherichia
Coli
Bacterial Extract vaccine available in the
U.S.
It is labeled f
or
use in cattle to help reduce the prevalence of E.
coli O157 in cattle and feces. This helps to minimize E.
coli exposure and infection of herd-mates.
As
part of its licensing agreement, Pfizer Animal Health also acquired global
rights to Epitopix’
conditionally licensed Salmonella
Newp
or
t
bacterial extract vaccine*. Currently available in the
U.S.
from Agri Lab
or
at
or
ies, Ltd., of
St. Joseph
,
Missouri
under a USDA conditional license, it will become an exclusive part of Pfizer
Animal Health’s livestock p
or
tfolio in the
U.S.
beginning in 2011
Pfizer
Animal Health and Epitopix will conduct additional potency and efficacy studies
on both vaccines to secure a full license f
or
each from the USDA. Terms of the global licensing agreement were not disclosed.
“The
R&D strength, global reach, and marketing expertise of Pfizer Animal Health
make it an ideal partner f
or
Epitopix,” said Epitopix General Manager Jim Sandstrom. “By w
or
king in close cooperation, our mutual aim is to quickly broaden the availability
of these imp
or
tant vaccines to the beef and dairy industries, as part of Pfizer Animal
Health’s comprehensive p
or
tfolio of cattle products and services.”
About
E. coli Infection in People
The
U.S. Centers f
or
Disease Control (CDC) estimates approximately 70,000 cases occur in people
annually. However, the CDC acknowledges that most cases of E.
coli O157 go unrep
or
ted. The
symptoms of E. coli O157 infections
vary f
or
each person but often include severe stomach cramps, diarrhea (often bloody),
and vomiting. If there is fever, it usually is not very high (less than
101˚F/less than 38.5˚C). Most people get better within 5–7 days.
Some infections are very mild, but others are severe
or
even life-threatening.
About
Epitopix
Epitopix
LLC was founded in 2002 as an affiliate of Willmar Poultry Company, a subsidiary
of Life-Science Innovations headquartered in
Willmar
,
Minn.
at the MinnWest Technology Campus, a 110 acre privately-owned technology
business park. The mission of Epitopix is to provide the food animal industry
with novel bacterial vaccines with the potential to be m
or
e broadly cross-protective and safer than conventional whole-cell bacterins
or
live bacterial vaccines. Epitopix owns a family of patents related to the
utilization of bacterial iron-acquisition proteins f
or
use as vaccine antigens. F
or
m
or
e inf
or
mation, visit www.Epitopix.com.
About
Pfizer Animal Health
Pfizer,
Inc, the w
or
ld’s largest research-based biomedical and pharmaceutical company, also is a w
or
ld leader in discovering and developing innovative animal vaccines and
prescription medicines, investing an estimated $300 million annually. In the
first quarter of 2010, Pfizer Animal Health generated revenue of $846 million,
and f
or
full-year 2009, $2.8 billion, including revenue from Wyeth/F
or
t Dodge since Pfizer’s acquisition in October.
In
addition to helping assure a safe, global food supply from healthy food animals,
Pfizer Animal Health also helps dogs, cats and h
or
ses to live healthy longer. F
or
additional inf
or
mation on Pfizer’s p
or
tfolio of animal products and services, visit www.PfizerAnimalHealth.com.
*Notice:
This product license is conditional. Efficacy and/
or
potency of this product have not been fully demonstrated. Consultation with a
veterinarian is recommended.
©2010
Pfizer Animal Health. All rights reserved. GCA10053.
###